Pioneering Next Generation Antibody Drug Conjugates (ADCs)

LATEST NEWS


February 19, 2025: ‘Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner‘Fierce Biotech


February 19, 2025: ‘Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate‘ – GlobalNewswire



January 8, 2024: ‘Biocytogen enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma‘ – Businesswire